Double-Blind Method

Efficacy and safety of baricitinib in hospitalized adults with severe or critical COVID-19 (Bari-SolidAct): a randomised, double-blind, placebo-controlled phase 3 trial
BACKGROUND: Baricitinib has shown efficacy in hospitalized patients with COVID-19, but no placebo-controlled trials have focused …
Marius Trøseid, José R. Arribas, Lambert Assoumou, Aleksander Rygh Holten, Julien Poissy, Vida Terzić, Fulvia Mazzaferri, Jesús Rodríguez-Baño, Joe Eustace, Maya Hites, Michael Joannidis, José Artur Paiva, Jean Reuter, Isabel Püntmann, Thale D. J. H. Patrick-Brown, Elin Westerheim, Katerina Nezvalova-Henriksen, Lydie Beniguel, Tuva Børresdatter Dahl, Maude Bouscambert, Monika Halanova, Zoltan Peterfi, Sotirios Tsiodras, Michael Rezek, Matthias Briel, Serhat Unal, Martin Schlegel, Florence Ader, Karine Lacombe, Cecilie Delphin Amdal, Serge Rodrigues, Kristian Tonby, Alexandre Gaudet, Lars Heggelund, Joy Mootien, Asgeir Johannessen, Jannicke Horjen Møller, Beatriz Diaz Pollan, Anders Aune Tveita, Anders Benjamin Kildal, Jean-Christophe Richard, Olav Dalgard, Victoria Charlotte Simensen, Aliou Baldé, Lucie De Gastines, Marta del Álamo, Burç Aydin, Fridtjof Lund-Johansen, Mary Anne Trabaud, Alpha Diallo, Bente Halvorsen, John-Arne Røttingen, Evelina Tacconelli, Yazdan Yazdanpanah, Inge C. Olsen, Dominique Costagliola, EU SolidAct study group
Cite DOI
Long-term efficacy and safety of biosimilar infliximab (CT-P13) after switching from originator infliximab: open-label extension of the NOR-SWITCH trial
BACKGROUND AND OBJECTIVES: The 52-week, randomized, double-blind, noninferiority, government-funded NOR-SWITCH trial demonstrated that …
G. L. Goll, K. K. Jørgensen, J. Sexton, I. C. Olsen, N. Bolstad, E. A. Haavardsholm, K. E. A. Lundin, K. S. Tveit, M. Lorentzen, I. P. Berset, B. T. S. Fevang, S. Kalstad, K. Ryggen, D. J. Warren, R. A. Klaasen, Ø Asak, S. Baigh, I. M. Blomgren, Ø Brenna, T. J. Bruun, K. Dvergsnes, S. O. Frigstad, I. M. Hansen, I. S. H. Hatten, G. Huppertz-Hauss, M. Henriksen, S. S. Hoie, J. Krogh, I. P. Midtgard, P. Mielnik, B. Moum, G. Noraberg, A. Poyan, U. Prestegård, H. U. Rashid, E. K. Strand, K. Skjetne, K. A. Seeberg, R. Torp, C. M. Ystrøm, C. Vold, C. C. Zettel, K. Waksvik, B. Gulbrandsen, J. Hagfors, C. Mørk, J. Jahnsen, T. K. Kvien
Cite DOI
Ibuprofen versus pivmecillinam for uncomplicated urinary tract infection in women-A double-blind, randomized non-inferiority trial
BACKGROUND: Although uncomplicated urinary tract infections (UTIs) are often self-limiting, most patients will be prescribed antibiotic …
Ingvild Vik, Marianne Bollestad, Nils Grude, Anders Bærheim, Eivind Damsgaard, Thomas Neumark, Lars Bjerrum, Gloria Cordoba, Inge Christoffer Olsen, Morten Lindbæk
Cite DOI
Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
BACKGROUND: TNF inhibitors have improved treatment of Crohn’s disease, ulcerative colitis, spondyloarthritis, rheumatoid …
Kristin K. Jørgensen, Inge C. Olsen, Guro L. Goll, Merete Lorentzen, Nils Bolstad, Espen A. Haavardsholm, Knut E. A. Lundin, Cato Mørk, Jørgen Jahnsen, Tore K. Kvien, NOR-SWITCH study group
Cite DOI
A 1-year randomized, double-blind, placebo-controlled study of intravenous ibandronate on bone loss following renal transplantation
The clinical profile of ibandronate as add-on to calcitriol and calcium was studied in this double-blind, placebo-controlled trial of …
K. T. Smerud, S. Dolgos, I. C. Olsen, A. Åsberg, S. Sagedal, A. V. Reisæter, K. Midtvedt, P. Pfeffer, T. Ueland, K. Godang, J. Bollerslev, A. Hartmann
Cite DOI
ω-3 fatty acid treatment in multiple sclerosis (OFAMS Study): a randomized, double-blind, placebo-controlled trial
OBJECTIVE: To investigate whether ω-3 fatty acids reduce magnetic resonance imaging (MRI) and clinical disease activity in patients …
Oivind Torkildsen, Stig Wergeland, Søren Bakke, Antonie G. Beiske, Kristian S. Bjerve, Harald Hovdal, Rune Midgard, Finn Lilleås, Tom Pedersen, Bård Bjørnarå, Frøydis Dalene, Grethe Kleveland, Jan Schepel, Inge Christoffer Olsen, Kjell-Morten Myhr
Cite DOI
Effect of piboserod, a 5-HT4 serotonin receptor antagonist, on left ventricular function in patients with symptomatic heart failure
AIMS: Myocardial 5-HT(4) serotonin (5-HT) receptors are increased and activated in heart failure (HF). Blockade of 5-HT(4) receptors …
John K. Kjekshus, Christian Torp-Pedersen, Lars Gullestad, Lars Køber, Thor Edvardsen, Inge C. Olsen, Ivar Sjaastad, Eirik Qvigstad, Tor Skomedal, Jan-Bjørn Osnes, Finn Olav Levy
Cite DOI
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
BACKGROUND: Treatment of relapsing-remitting multiple sclerosis with interferon beta is only partly effective, and new more effective …
Per Soelberg Sorensen, Svein Ivar Mellgren, Anders Svenningsson, Irina Elovaara, Jette Lautrup Frederiksen, Antonie Giaever Beiske, Kjell-Morten Myhr, Lise Vejby Søgaard, Inge Christoffer Olsen, Magnhild Sandberg-Wollheim
Cite DOI
Effect of oxcarbazepine in the treatment of agitation and aggression in severe dementia
BACKGROUND/AIMS: To evaluate the efficacy of oxcarbazepine (OXC) in the treatment of agitation and aggression in patients with …
Oskar H. Sommer, Olav Aga, Milada Cvancarova, Inge C. Olsen, Geir Selbaek, Knut Engedal
Cite DOI